You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Forest Laboratories LLC v. Sigmapharm Laboratories LLC
The small molecule drug covered by the patents cited in this case is ⤷  Sign Up .

Details for Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2014-09-03 1 paragraphs 1-20. 22, United States Patent No. 7,741,358 (“the ’358 patent”), titled “Crystal Forrn of Asenapine…United States Patent No. 7,741,358 constitute infringement of one or more claims of said patent under 35 U.S.C…: a) declare that United States Patent Nos. 5,763,476 and 7,741,358 are valid; b) declare that, under…Sigmapharm infringed United States Patent Nos. 5,763,476 and 7,741,358 by submitting ANDA No. 206107 to …expiration date of United States Patent Nos. 5,763,476 and 7,741,358, including any exclusivities or extensions External link to document
2016-01-28 133 language of U.S. Patent Nos. 5,763,476, (the '476 patent), 7,741,358 (the '358 patent), and 8,022,228…1 of the '228 patent which shares a specification with the '358 patent. All references in …8,022,228 (the '228 patent) shall be construed consistent with the tenets of claim construction … The '476 Patent 1. "Tension, excitation, anxiety…the time, evidenced by applicants' separate patent application (No. 11/247,342) for the treatment External link to document
2016-03-24 174 and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228 (Hikma and West-Ward) by Forest… 14 September 2020 1:14-cv-01119 830 Patent None District Court, D. Delaware External link to document
2016-04-11 179 crystalline form, as required by claim 1 of U.S. Patent No. 7,741,358. An issue that not atypically arises in … 14 September 2020 1:14-cv-01119 830 Patent None District Court, D. Delaware External link to document
2016-04-15 181 and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228 (between Plaintiffs and Sigmapharm… 14 September 2020 1:14-cv-01119 830 Patent None District Court, D. Delaware External link to document
2017-07-11 325 and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228" (D.1. 174 in C.A. … and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228" (D.I. 181 in C.A. …9 PageID #: 9476 U.S. Patent No. 5,763,476 (the '"476 Patent") by submitting to the…of the expiration of the '4 76 Patent inclusive of the patent term extension granted under 35 U.S.C…'476 Patent on Plaintiffs' Counts I and II in their "Complaint for Patent Infringement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.